| Title |
Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
|
|---|---|
| Published in |
Clinical and Translational Oncology, July 2012
|
| DOI | 10.1007/s12094-012-0858-3 |
| Pubmed ID | |
| Authors |
Carlos Gómez-Martin, Antonio Sánchez, Antonio Irigoyen, Beatriz Llorente, Begoña Pérez, Raquel Serrano, Mª José Safont, Esther Falcó, Adelaida Lacasta, Margarita Reboredo, Jorge Aparicio, Rosario Dueñas, Marta Llanos Muñoz, Pilar Regueiro, Elena Sanchez-Viñes, Rafael López López |
| Abstract |
Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 6% |
| Unknown | 30 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 19% |
| Librarian | 5 | 16% |
| Student > Doctoral Student | 4 | 13% |
| Student > Bachelor | 3 | 9% |
| Other | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 8 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 41% |
| Nursing and Health Professions | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Computer Science | 1 | 3% |
| Unknown | 14 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2012.
All research outputs
#18,316,001
of 22,679,690 outputs
Outputs from Clinical and Translational Oncology
#839
of 1,283 outputs
Outputs of similar age
#125,761
of 163,949 outputs
Outputs of similar age from Clinical and Translational Oncology
#26
of 43 outputs
Altmetric has tracked 22,679,690 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,283 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,949 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.